PRM.TO
Big Pharma Split Corp. [PRM.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PRM.TO Stock Summary
In the News
PRM.TO Financial details
Company Rating
Sell
Market Cap
16.34M
Income
-236.81K
Revenue
2.65M
Book val./share
-
Cash/share
-
Dividend
1.24
Dividend %
8.41%
Employees
-
Optionable
No
Shortable
Yes
Earnings
30 Mar 2023
P/E
7.05
Forward P/E
-
PEG
-0.61
P/S
4.83
P/B
1.12
P/C
-
P/FCF
15.88
Quick Ratio
42.61
Current Ratio
42.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.24
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-33.7%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
8%
ROE
15%
ROC
0.08%
Gross Margin
100%
Oper. Margin
85%
Profit Margin
85%
Payout
83%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
13.2-16.04
52W High
-16.81%
52W Low
+2.38%
RSI
35
Rel Volume
1.4
Avg Volume
1.03K
Volume
1.43K
Perf Week
-3.9%
Perf Month
-6.6%
Perf Quarter
-
Perf Half Y
-8.21%
-
-
-
-
Beta
0.879
-
-
Volatility
0.12%, 0.38%
Prev Close
0.08%
Price
13.31
Change
-0.89%
PRM.TO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.04 | 0.59 | 4.16 | 2.46 | 0 | |
| Net income per share | 3.75 | 0.27 | 3.76 | 2.08 | 0 | |
| Operating cash flow per share | 7.26 | 4.37 | -6.98 | 0.75 | 0 | |
| Free cash flow per share | 7.26 | 4.37 | -6.98 | 0.75 | 0 | |
| Cash per share | 22.46 | 0.23 | 1.11 | 0.54 | 0 | |
| Book value per share | 13.64 | 13.24 | 17.38 | 13.07 | 0 | |
| Tangible book value per share | 13.64 | 22.82 | 29.07 | 13.07 | 0 | |
| Share holders equity per share | 13.64 | 13.24 | 17.38 | 13.07 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 16.8M | 13.34M | 18.91M | 22M | 0 | |
| Enterprise value | 16.27M | 13.11M | 17.48M | 21.19M | -204.19K | |
| P/E ratio | 3.74 | 50.27 | 3.9 | 7 | 0 | |
| Price to sales ratio | 6.9 | 22.65 | 3.53 | 5.93 | 0 | |
| POCF ratio | 1.94 | 3.07 | -2.1 | 19.5 | 0 | |
| PFCF ratio | 1.94 | 3.07 | -2.1 | 19.5 | 0 | |
| P/B Ratio | 1.03 | 1.01 | 0.84 | 1.12 | 0 | |
| PTB ratio | 1.03 | 1.01 | 0.84 | 1.12 | 0 | |
| EV to sales | 6.68 | 22.25 | 3.26 | 5.71 | -0.65 | |
| Enterprise value over EBITDA | 35.78 | 49.4 | 3.6 | 6.74 | 1.46 | |
| EV to operating cash flow | 1.87 | 3.02 | -1.94 | 18.77 | -0.02 | |
| EV to free cash flow | 1.87 | 3.02 | -1.94 | 18.77 | -0.02 | |
| Earnings yield | 0.27 | 0.02 | 0.26 | 0.14 | 0 | |
| Free cash flow yield | 0.52 | 0.33 | -0.48 | 0.05 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -1.18 | -0.87 | -0.29 | -0.26 | 1.46 | |
| Current ratio | 2.5 | 1.57 | 4.52 | 42.61 | 1.13 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 3.36 | -20 | -2.14 | 0.47 | -18.38 | |
| Dividend Yield | 0.12 | 0.13 | 0.15 | 0.12 | 0 | |
| Payout ratio | 0.46 | 6.52 | 0.58 | 0.83 | -15.1 | |
| Sales general and administrative to revenue | 0.12 | 0.37 | 0.07 | 0.1 | 1.07 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 33.93 | 8.91 | 38.36 | 24.76 | 0 | |
| ROIC | 0.04 | 0.04 | 0.03 | 0.04 | -0.01 | |
| Return on tangible assets | 0.17 | 0.01 | 0.13 | 0.08 | -0.01 | |
| Graham Net | 13.42 | 0 | 0.53 | -5.51 | 0 | |
| Working capital | 16.31M | 122.03K | 1.19M | 14.48M | 32.63K | |
| Tangible asset value | 16.31M | 22.72M | 37.48M | 19.73M | 26.29M | |
| Net current asset value | 16.31M | 122.03K | 1.19M | -4.54M | 32.63K | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 71.57K | 88.67K | 103.44K | 7.05M | 7.04M | |
| Average payables | 152.93K | 106.61K | 276.12K | 343.43K | 298.26K | |
| Average inventory | 0 | -97.23K | -579.3K | -754.64K | -272.57K | |
| Days sales outstanding | 10.96 | 64.58 | 6.99 | 1.38K | 90.28 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 33.31 | 5.65 | 52.23 | 0.26 | 4.04 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.28 | 0.02 | 0.22 | 0.16 | -0.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.01 | 1.01 | -0.16 | -0.16 | 0 | |
| Net income per share | 0.11 | 0.11 | -0.23 | -0.23 | 0 | |
| Operating cash flow per share | 0.33 | 0.33 | 4.24 | 4.24 | 0 | |
| Free cash flow per share | 0.33 | 0.33 | 4.24 | 4.24 | 0 | |
| Cash per share | 0.54 | 0.54 | 0.32 | 0.32 | 0 | |
| Book value per share | 13.04 | 13.04 | 14 | 14 | 0 | |
| Tangible book value per share | 13.04 | 13.04 | 14 | 22.11 | 0 | |
| Share holders equity per share | 13.04 | 13.04 | 14 | 14 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 19.71M | 22.06M | 17.84M | 18.29M | 0 | |
| Enterprise value | 18.89M | 21.24M | 17.45M | 17.9M | -204.19K | |
| P/E ratio | 29.82 | 33.37 | -15.73 | -16.12 | 0 | |
| Price to sales ratio | 12.94 | 14.48 | -89.57 | -91.83 | 0 | |
| POCF ratio | 39 | 43.64 | 3.38 | 3.46 | 0 | |
| PFCF ratio | 39 | 43.64 | 3.38 | 3.46 | 0 | |
| P/B Ratio | 1 | 1.12 | 1.02 | 1.05 | 0 | |
| PTB ratio | 1 | 1.12 | 1.02 | 1.05 | 0 | |
| EV to sales | 12.4 | 13.94 | -87.58 | -89.83 | 0 | |
| Enterprise value over EBITDA | -16.55 | -18.61 | 210.81 | 216.24 | 0 | |
| EV to operating cash flow | 37.38 | 42.02 | 3.3 | 3.39 | 0 | |
| EV to free cash flow | 37.38 | 42.02 | 3.3 | 3.39 | 0 | |
| Earnings yield | 0.01 | 0.01 | -0.02 | -0.02 | 0 | |
| Free cash flow yield | 0.03 | 0.02 | 0.3 | 0.29 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.72 | 0.72 | -4.8 | -4.8 | 0 | |
| Current ratio | 0.79 | 42.61 | 0.08 | 1.93 | 1.13 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 3.06 | 3.06 | -18.63 | -18.63 | 0 | |
| Dividend Yield | 0.03 | 0.03 | 0.03 | 0.03 | 0 | |
| Payout ratio | 3.98 | 3.98 | -1.97 | -1.97 | 0 | |
| Sales general and administrative to revenue | 0.13 | 0.13 | -0.69 | -0.69 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.66 | 5.66 | 8.46 | 8.46 | 0 | |
| ROIC | 0.52 | 0.52 | -0.03 | -0.03 | 0 | |
| Return on tangible assets | 0 | 0 | -0.01 | -0.01 | 0 | |
| Graham Net | -5.32 | -5.5 | -7.94 | 0.02 | 0 | |
| Working capital | -4M | 14.48M | -9.5M | 234.12K | 32.63K | |
| Tangible asset value | 19.73M | 19.73M | 17.47M | 27.58M | 26.29M | |
| Net current asset value | -4M | -4.54M | -9.5M | 234.12K | 32.63K | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 7.07M | 14M | 7.05M | 87.12K | 0 | |
| Average payables | 172.67K | 173.92K | 173.92K | 125.26K | 0 | |
| Average inventory | 0.5 | -272.57K | -272.57K | -191.94K | 0 | |
| Days sales outstanding | 827.09 | 827.09 | -39.36 | -39.36 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.11 | 0.11 | -2.29 | -2.29 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.01 | 0.01 | -0.02 | -0.02 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
PRM.TO Frequently Asked Questions
What is Big Pharma Split Corp. stock symbol ?
Big Pharma Split Corp. is a CA stock , located in Oakville of On and trading under the symbol PRM.TO
What is Big Pharma Split Corp. stock quote today ?
Big Pharma Split Corp. stock price is $13.31 today.
Is Big Pharma Split Corp. stock public?
Yes, Big Pharma Split Corp. is a publicly traded company.
Company Profile
- Volume Average 1.03K
- Market Capitalization 16.34M
- CEO Louis Michael Kovacs
- Headquarters Oakville,ON,CA
- IPO Date 2017-11-27
-
Website
https://www.harvestportfolios.com/closed-end-funds/big-pharma-split-corp/ 
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.
